Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd..
Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection. We report a case series of adult patients with B cell malignancies and/or undergoing B cell targeting therapies with persisting SARS-CoV-2 infection and treated with a combination antiviral therapy of remdesivir and nirmatrelvir/ritonavir, in three Italian tertiary academic hospitals. A total of 14 patients with impaired adaptive humoral immunity and prolonged SARS-CoV-2 infection were treated with the dual antiviral therapy. The median age was 60 (IQR 56-68) years, and 11 were male. Twelve patients had B cell lymphoma, one patient had chronic lymphocytic leukemia and one patient had multiple sclerosis. Thirteen out of 14 patients had received prior B cell-targeting therapies, consisting of anti-CD20 monoclonal antibodies in 11 patients, and chimeric antigen receptor T therapy in 2 patients. The median time between diagnosis and therapy start was 42.0 (IQR 35-46) days. Seven patients had mild, 6 moderate and one severe disease. Nine patients had signs of interstitial pneumonitis on chest computed tomography scans before treatment. The median duration of nirmatrelvir/ritonavir and remdesivir combination therapy was 10 days. All patients showed resolution of COVID-19-related symptoms after a median of 6 (IQR 4-11) days and viral clearance after 9 (IQR 5-11) days. Combination therapy with remdesivir and nirmatrelvir/ritonavir is a promising treatment option for persistent COVID-19 in immunocompromized patients with humoral immunity impairment, worthy of prospective comparative trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Hematological oncology - 41(2023), 5 vom: 14. Dez., Seite 904-911 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasquini, Zeno [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359533027 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359533027 | ||
| 003 | DE-627 | ||
| 005 | 20231227132913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM359533027 | ||
| 035 | |a (NLM)37452579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasquini, Zeno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd. | ||
| 520 | |a Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection. We report a case series of adult patients with B cell malignancies and/or undergoing B cell targeting therapies with persisting SARS-CoV-2 infection and treated with a combination antiviral therapy of remdesivir and nirmatrelvir/ritonavir, in three Italian tertiary academic hospitals. A total of 14 patients with impaired adaptive humoral immunity and prolonged SARS-CoV-2 infection were treated with the dual antiviral therapy. The median age was 60 (IQR 56-68) years, and 11 were male. Twelve patients had B cell lymphoma, one patient had chronic lymphocytic leukemia and one patient had multiple sclerosis. Thirteen out of 14 patients had received prior B cell-targeting therapies, consisting of anti-CD20 monoclonal antibodies in 11 patients, and chimeric antigen receptor T therapy in 2 patients. The median time between diagnosis and therapy start was 42.0 (IQR 35-46) days. Seven patients had mild, 6 moderate and one severe disease. Nine patients had signs of interstitial pneumonitis on chest computed tomography scans before treatment. The median duration of nirmatrelvir/ritonavir and remdesivir combination therapy was 10 days. All patients showed resolution of COVID-19-related symptoms after a median of 6 (IQR 4-11) days and viral clearance after 9 (IQR 5-11) days. Combination therapy with remdesivir and nirmatrelvir/ritonavir is a promising treatment option for persistent COVID-19 in immunocompromized patients with humoral immunity impairment, worthy of prospective comparative trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B cell malignancies | |
| 650 | 4 | |a B cell targeting therapies | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a persistent SARS-CoV-2 infection | |
| 650 | 4 | |a viral infections in the hematological patient | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Toschi, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Casadei, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Pellegrini, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Abramo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vita, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Beccacece, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Bussini, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Chionsini, Maria Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Dentale, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Cantiani, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzarotto, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoletti, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Zinzani, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Giannella, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Pierluigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 41(2023), 5 vom: 14. Dez., Seite 904-911 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:5 |g day:14 |g month:12 |g pages:904-911 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 5 |b 14 |c 12 |h 904-911 | ||